The future perspectives of breast cancer therapy

Biomedicine and Pharmacotherapy

Volumn 60, Issue 6, 2006, Pages 259-262

  Chow, L W C ^a,b,c   Yiu, C C P ^b   Yip, A Y S ^c   Loo, W T Y ^a  

^a UNIMED Medical Institute   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c Organisation for Oncology and Translational Research   (Hong Kong)

Author keywords

Breast cancer; Future perspectives; Therapy

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CELECOXIB; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; GEMCITABINE; LAPATINIB; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB; ANTINEOPLASTIC AGENT;

ANGIOGENESIS; APOPTOSIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; MULTIDRUG RESISTANCE; PEROPERATIVE CARE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT SURVEY; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BREAST TUMOR; DRUG RESISTANCE; FEMALE; REVIEW; TREATMENT OUTCOME; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; TREATMENT OUTCOME;

EID: 33747121927     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2006.06.010     Document Type: Short Survey

References (27)

1. Toi M., Bando H., and Chow L.W. Novel insights in clinical trials with preoperative systemic therapy for primary breast cancer. Biomed. Pharmacother. 58 (2004) 531-535
2. Wolmark N., Wang J., Mamounas E., et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J. Natl. Cancer Inst. Monogr. 30 (2001) 96-102
3. Smith I.E., and Lipton L. Preoperative/neoadjuvant medical therapy for early breast cancer. Lancet Oncol. 2 (2001) 561-570
4. Bear H.D., Anderson S., Smith R.E., et al. Sequential Preoperative or Postoperative Docetaxel Added to Preoperative Doxorubicin Plus Cyclophosphamide for Operable Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. (2006) (Apr 10; [Epub ahead of print])
5. Ohnoa S., Toi M., Kuroi K., et al. Update results of FEC followed by docetaxel neoadjuvant trials for primary breast cancer. Biomed. Pharmacother. 59 Suppl 2 (2005) S323-S324
6. Toi M., Bando H., Horiguchi S., et al. Modulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancer. Br. J. Cancer 90 12 (2004) 2338-2343
7. Miles D., Vukelja S., Moiseyenko V., et al. Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trial. Clin. Breast Cancer 5 4 (2004) 273-278
8. Mercer S.J., Di Nicolantonio F., Knight L.A., et al. Rapid up-regulation of cyclooxygenase-2 by 5-fluorouracil in human solid tumors. Anticancer Drugs 16 5 (2005) 495-500
9. Buchholz T.A., Garg A.K., Chakravarti N., et al. The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer. Clin. Cancer Res. 11 23 (2005) 8398-8402
10. Menard S., Caslini P., Tomasic G., et al. Pathobiologic identification of two distinct breast carcinoma subsets with diverging clinical behaviors. Breast Cancer Res. Treat. 55 2 (1999) 169-177
11. Pegram M.D., Konecny G.E., O'Callaghan C., et al. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J. Natl. Cancer Inst. 96 10 (2004) 739-749
12. Marty M., Cognetti F., Maraninchi D., et al. Efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: results of a randomized phase II trial by the M7701 study group. J. Clin. Oncol. 23 19 (2005) 4265-4274
13. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353 16 (2005) 1659-1672
14. Burstein H.J., Harris L.N., Gelman R., et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J. Clin. Oncol. 21 1 (2003) 46-53
15. Buzdar A.U., Ibrahim N.K., Francis D., et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J. Clin. Oncol. 23 16 (2005) 3676-3685
16. Burris III H.A., Hurwitz H.I., Dees E.C., et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J. Clin. Oncol. 23 23 (2005) 5305-5313
17. Gomez HL, Chavez MA, Doval DC, et al. A phase II, randomized trial using the small molecule tyrosine kinase inhibitor lapatinib as a first-line treatment in patients with FISH positive advanced or metastatic breast cancer. Presented in American Society of Clinical Oncology Annual Meeting 2005.
18. Wedam S.B., Low J.A., Yang S.X., et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J. Clin. Oncol. 24 5 (2006) 769-777
19. Paik S., Shak S., Tang G., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351 (2004) 2817-2826
20. Foekens J.A., Atkins D., Zhang Y., et al. Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J. Clin. Oncol. 24 11 (2006) 1665-1671
21. Graham C.H., Kobayaashi H., Stankiewicz K.S., et al. Rapid acquisition of multicellular drug resistance after a single exposure of mammary tumour cells to antitumour alkylating agents. J Natl Cnacer Inst. 86 13 (1994) 975-982
22. Loo T.W., and Clarke D.M. Recent progress in understanding the mechanism of P-glycoprotein-mediated drug efflux. J. Membr. Biol. 206 3 (2005) 173-185 (Review)
23. Chevillard S., Pouillart P., Beldjord C., et al. Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy. Cancer 77 2 (1996) 292-300
24. Chung H.C., Rha S.Y., Kim J.H., et al. P-glycoprotein: the intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer. Breast Cancer Res. Treat. 42 1 (1997) 65-72
25. Verrelle P., Meissonnier F., Fonck Y., et al. Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma. J. Natl. Cancer Inst. 83 2 (1991) 111-116
26. Burger H., Fookens J.A., Look M.P., et al. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-related protein 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. Clin. Cancer Res. 9 2 (2003) 827-836
27. Schneider E., Horton J.K., Yang C.H., et al. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Cancer Res. 54 1 (1994) 152-158